X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs CIPLA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS CIPLA NOVARTIS/
CIPLA
 
P/E (TTM) x 363.2 45.1 805.8% View Chart
P/BV x 17.9 3.9 462.7% View Chart
Dividend Yield % 1.6 0.3 485.8%  

Financials

 NOVARTIS   CIPLA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
CIPLA
Mar-17
NOVARTIS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs982622 157.9%   
Low Rs556458 121.4%   
Sales per share (Unadj.) Rs252.9181.9 139.1%  
Earnings per share (Unadj.) Rs62.112.9 482.8%  
Cash flow per share (Unadj.) Rs63.329.3 215.9%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.4 351.1%  
Book value per share (Unadj.) Rs363.6155.7 233.6%  
Shares outstanding (eoy) m31.96804.51 4.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.03.0 102.4%   
Avg P/E ratio x12.442.0 29.5%  
P/CF ratio (eoy) x12.218.4 66.0%  
Price / Book Value ratio x2.13.5 61.0%  
Dividend payout %16.115.5 103.6%   
Avg Mkt Cap Rs m24,580434,516 5.7%   
No. of employees `0000.823.0 3.3%   
Total wages/salary Rs m1,80126,338 6.8%   
Avg. sales/employee Rs Th10,748.96,349.1 169.3%   
Avg. wages/employee Rs Th2,395.21,143.0 209.6%   
Avg. net profit/employee Rs Th2,641.1449.3 587.8%   
INCOME DATA
Net Sales Rs m8,083146,302 5.5%  
Other income Rs m8292,287 36.3%   
Total revenues Rs m8,913148,589 6.0%   
Gross profit Rs m23424,758 0.9%  
Depreciation Rs m3713,229 0.3%   
Interest Rs m21,594 0.1%   
Profit before tax Rs m1,02512,222 8.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m17-70 -23.9%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7521,798 41.8%   
Profit after tax Rs m1,98610,354 19.2%  
Gross profit margin %2.916.9 17.1%  
Effective tax rate %73.414.7 498.8%   
Net profit margin %24.67.1 347.2%  
BALANCE SHEET DATA
Current assets Rs m12,67887,370 14.5%   
Current liabilities Rs m2,43333,081 7.4%   
Net working cap to sales %126.737.1 341.6%  
Current ratio x5.22.6 197.3%  
Inventory Days Days3387 37.6%  
Debtors Days Days2262 36.1%  
Net fixed assets Rs m69111,567 0.1%   
Share capital Rs m1601,609 9.9%   
"Free" reserves Rs m11,460123,645 9.3%   
Net worth Rs m11,621125,254 9.3%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m14,400209,532 6.9%  
Interest coverage x570.58.7 6,581.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.7 80.4%   
Return on assets %13.85.7 242.1%  
Return on equity %17.18.3 206.7%  
Return on capital %23.68.5 277.4%  
Exports to sales %0.734.2 2.2%   
Imports to sales %18.68.3 222.9%   
Exports (fob) Rs m6050,050 0.1%   
Imports (cif) Rs m1,50312,203 12.3%   
Fx inflow Rs m18651,066 0.4%   
Fx outflow Rs m1,82117,678 10.3%   
Net fx Rs m-1,63533,388 -4.9%   
CASH FLOW
From Operations Rs m2,53123,824 10.6%  
From Investments Rs m-8,270-13,127 63.0%  
From Financial Activity Rs m-386-13,239 2.9%  
Net Cashflow Rs m-6,125-2,478 247.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 2.0 12.2 16.4%  
FIIs % 1.6 23.7 6.8%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.5 26.2 82.1%  
Shareholders   41,647 161,166 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 20, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS